Related Experiment Video
Updated: Mar 28, 2026

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans
Published on: October 5, 2020
The Nrf2/HO-1 Axis in Cancer Cell Growth and Chemoresistance
A L Furfaro1, N Traverso2, C Domenicotti2
1Giannina Gaslini Institute, Via Gerolamo Gaslini 5, 16147 Genoa, Italy.
The nuclear factor erythroid 2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1) pathway regulates cellular defense against stress. Targeting this Nrf2/HO-1 mechanism offers a promising strategy to overcome cancer therapy resistance.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Nuclear factor erythroid 2-related factor 2 (Nrf2) is a transcription factor that regulates cellular redox homeostasis.
- Nrf2 activation leads to the expression of antioxidant and detoxifying genes, including heme oxygenase 1 (HO-1).
- Elevated Nrf2 and HO-1 are observed in various cancers, correlating with poor prognosis and therapeutic resistance.
Purpose of the Study:
- To review the Nrf2/HO-1 stress response pathway.
- To explore its role in cancer progression and therapeutic resistance.
- To highlight the potential of targeting Nrf2/HO-1 as an anticancer strategy.
Main Methods:
- Literature review of studies on Nrf2, HO-1, and cancer.
- Analysis of the molecular mechanisms underlying Nrf2/HO-1 activation in cancer.
- Examination of preclinical and clinical data on targeting Nrf2/HO-1 in cancer therapy.
Main Results:
- The Nrf2/HO-1 pathway is a key regulator of cellular defense against oxidative and electrophilic stress.
- Upregulation of Nrf2 and HO-1 contributes to tumor progression, aggressiveness, and resistance to conventional therapies.
- Inhibition of the Nrf2/HO-1 pathway shows potential in overcoming therapeutic resistance in various cancer types.
Conclusions:
- The Nrf2/HO-1 pathway is a critical mediator of cancer cell survival and therapeutic resistance.
- Targeting this pathway represents a promising approach for developing novel anticancer treatments.
- Further research is warranted to fully elucidate the therapeutic potential of Nrf2/HO-1 inhibitors in oncology.
Related Concept Videos
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
Treatment Resistant Cancers
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:

